ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes
- DOI
- 10.1111/dom.15827
- Published
- 2024-08-07
- Container
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1111/dom.15827,
title = {ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes},
author = {Grit Andersen and Rosy Eloy and Tim Heise and Martin Gaudier and Claire Mégret and Cyril Seroussi and You‐Ping Chan and Olivier Soula and Matthew Riddle and J. Hans DeVries},
year = {2024},
journal = {Diabetes, Obesity and Metabolism},
doi = {10.1111/dom.15827},
url = {https://doi.org/10.1111/dom.15827}
}RIS
TY - JOUR TI - ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes AU - Grit Andersen AU - Rosy Eloy AU - Tim Heise AU - Martin Gaudier AU - Claire Mégret AU - Cyril Seroussi AU - You‐Ping Chan AU - Olivier Soula AU - Matthew Riddle AU - J. Hans DeVries PY - 2024 JO - Diabetes, Obesity and Metabolism DO - 10.1111/dom.15827 UR - https://doi.org/10.1111/dom.15827 ER -
APA
Andersen, G., Eloy, R., Heise, T., Gaudier, M., Mégret, C., Seroussi, C., Chan, Y., Soula, O., Riddle, M., & DeVries, J. H. (2024). ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15827
Source records
- crossref · retrieved 2026-09-26T10:49:24.236Z